Document Detail

Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
MedLine Citation:
PMID:  15548142     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The aim of this study was to investigate the prostanoid production in pregnancies at high risk for hypertensive disorders, and the effect of low-dose acetylsalicylic acid (ASA) on prostanoids. MATERIAL AND METHODS: Ninety women with a bilateral notching in uterine arteries screened by Doppler ultrasound at 12-14 gestational weeks were randomized to the ASA (0.5 mg/kg/day) or placebo group. Forty-three women in both groups were followed up throughout the pregnancy. Urine samples were taken at baseline, and at 24-26 and 32-34 weeks of gestation to determine the urinary 11-dehydrothromboxane B(2) (u-11-dehydro-TxB(2)) and 2,3-dinor-6-keto-prostaglandin F(1alpha) (u-2,3-dinor-6-keto-PGF(1alpha)), the metabolites of thromboxane A(2) and prostacyclin, respectively. RESULTS: In the pregnancies with pregnancy-induced hypertension (PIH) before 37 gestational weeks, the 2,3-dinor-6-keto-PGF(1alpha)/11-dehydro-TxB(2) ratio did not increase as much as in other pregnancies (P = 0.028). In the placebo group pregnancies with preeclampsia had significantly lower 2,3-dinor-6-keto-PGF(1alpha) (P = 0.019) at 12-14 weeks of gestation compared to other pregnancies. In the placebo group the 2,3-dinor-6-keto-PGF(1alpha)/11-dehydroTxB(2) ratio remained unchanged throughout the pregnancy, with no significant difference between pregnancies with a normal or an adverse outcome. In the ASA group the 2,3-dinor-6-keto-PGF(1alpha)/11-dehydro-TxB(2) ratio increased (P < 0.001, early vs. midpregnancy). Again, the changes were similar in pregnancies with a normal or an adverse outcome. CONCLUSION: The balance of prostacyclin and thromboxane A(2) shifted in an unfavorable direction in pregnancies complicated by PIH. ASA had a favorable effect on the prostanoids.
Merja Vainio; Asko Riutta; Anna-Maija Koivisto; Johanna Mäenpää
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica     Volume:  83     ISSN:  0001-6349     ISO Abbreviation:  Acta Obstet Gynecol Scand     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-11-19     Completed Date:  2004-12-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370343     Medline TA:  Acta Obstet Gynecol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  1119-23     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Hyvinkää Hospital, Hyvinkää, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
6-Ketoprostaglandin F1 alpha / analogs & derivatives*,  urine
Aspirin / administration & dosage*
Cyclooxygenase Inhibitors / administration & dosage*
Epoprostenol / analogs & derivatives,  metabolism*,  urine
Hypertension, Pregnancy-Induced / drug therapy*,  urine
Longitudinal Studies
Pregnancy Complications, Cardiovascular / drug therapy*,  urine
Pregnancy Outcome
Pregnancy, High-Risk
Prostaglandins / metabolism
Thromboxane A2 / analogs & derivatives,  metabolism*,  urine
Thromboxane B2 / analogs & derivatives*,  urine
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Prostaglandins; 35121-78-9/Epoprostenol; 50-78-2/Aspirin; 54397-85-2/Thromboxane B2; 57576-52-0/Thromboxane A2; 58962-34-8/6-Ketoprostaglandin F1 alpha; 64700-71-6/2,3-dinor-6-ketoprostaglandin F1alpha; 67910-12-7/11-dehydro-thromboxane B2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Well-being and sense of coherence during pregnancy.
Next Document:  Major congenital heart disease in Northern Norway: shortcomings of pre- and postnatal diagnosis.